Arnold returned to the company and gathered the company's scientific research apes, and then described in detail what he saw in Huarui Laboratory. Although the part that cannot be said in the confidentiality agreement was omitted, his description was enough for researchers to refer to.

In fact, the confidentiality agreement was originally something that Yang Rui prevented before it happened. There was no mysterious information in his laboratory that could be taken away by seeing it.

Arnold finished his description and asked, "Do you think there is hope? Yang Rui's deferrosterone project."

After several researchers whispered, the new chief technology officer, Van Lunding, said: "As far as we know, if the conditions are known, there will be no problem with the active substance. As long as the active substance is made, there is a need to continue doing it."

Van Lunding came to replace Trapp, who, as a well-known biological and chemical expert, came to help when it was launched in China.

Compared to the professor at Sheffield University, Van Luntin has a slightly inferior qualification. His most prominent achievement is that he has participated in the Olympics as a Cambridge-born rowing rower, and that's all.

Fan Lunding has not had much contact with Yang Rui, so he said purely from the perspective of scientific research: "I don't think it is a good idea to do drug research in China. Even if he is selling his company for a good price, it is not worth making original medicines. If he takes the route of rare drugs, it can indeed save a lot of trouble, but it is still very troublesome and is not the right choice."

"He has already chosen. I think the key to the problem should be, do you think Yang Rui can succeed?" Arnold asked very seriously. This is indeed a key issue.

Van Lunding thought for a moment, but did not dare to deny it completely, saying, "This is not easy to judge, but you know, even if 100 active substances are synthesized, it may not pass the animal test, let alone the human clinical trial, he is still far from success."

Other researchers also nodded, saying that they were not optimistic about Yang Rui's research.

Jielikan's researcher in China is mainly responsible for solving the production problems of the Coenzyme Q10 factory, and also helping Chinese partners build new factories. He has also dealt with Yang Rui.

However, they used to regard Yang Rui as a figure in the academic world, but now they have seen him enter the industry, and they all reveal the inherent prejudice of industrialists towards academic people.

"It is not that easy to develop original medicines, and it is difficult for Yang Rui to succeed."

“It’s unlikely to succeed.”

"Maybe he wants to sell us the active substances he made?"

"It's necessary to pass animal experiments to have the value of selling."

After listening to their discussion, Arnold changed some of his thoughts and said, "As far as I know, Yang Rui has a very good record. Now he is involved in making ferrosterone, so he may have some trump card."

Fan Lunding smiled and said, "It's nothing strange for every scientific researcher to be confident that he can succeed before starting the experiment. As a result, you see, how many drugs can be successful in the end? There are too many researchers in our company with great achievements, so who can guarantee that their next new drug will succeed."

Arnold lowered his head and thought, suddenly made an expression of thinking something, shook his head, and asked, "Van Lunding, I remember you had done new drug development before?"

"right."

“What’s the result?”

"The project failed, the company reorganized the project team, and failed again, the company reorganized the team, and continued to fail, and the company added additional investment, but it still failed, and the project team was finally disbanded." Fan Lunding described the seven years that once belonged to him in the simplest way.

Arnold seemed to be unaware of anything and asked, "Which step did you do?"

“Stage II of clinical practice.”

"From target screening, to drug synthesis, to animal experiments, then to clinical phase I and clinical phase II... I'm sorry to give up in the final stage." Arnold doesn't know much about scientific research, but he still knows very well about project management and other aspects.

"Although I'm sorry, the effectiveness test failed. If it continues, it will only cost more money." Fan Lunding spoke from the company's standpoint without expression.

Phase I of clinical trials is the safety trial phase of the drug, which is usually conducted in 20 to 40 healthy volunteers, and costs less than $1 million.

The second phase of clinical trials is the drug effectiveness trial stage, which requires 100 to 300 patients, and the cost is usually more than US$20 million.

As for the third phase of clinical trials, it is a large-scale verification stage for the safety and effectiveness of the drug. Since it is a large scale, a large number of people are indispensable. In the non-rare drug tests, the number of people in the third phase of clinical trials will usually increase to 20,000, and the cost will also reach an astonishing $100 million.

It can be imagined that no company will rashly advance the progress of clinical trials without considerable confidence.

When Arnold thought of this, he thought about what Yang Rui was doing now, and couldn't help but pull Fan Lunding aside and whispered: "You think of a way to let Yang Rui advance the research progress quickly and expand the research scale. Can you do it?"

"Why?" Van Lunding felt very surprised.

"You don't want to manage it, just do what I said." Arnold thought about it and laughed.

His main purpose of coming to China was to acquire the catalyst formula of Coenzyme Q10. The delay of two months was almost his limit.

However, Yang Rui did not seem to be affected by time delay, which made Arnold not only depressed but also worried.

In his opinion, the main reason for this problem is that Yang Rui did not have an urgent desire for funds.

Yang Rui's biggest expense is the expense of attorney fees, which is nearly one million US dollars a month, which fully proves the seriousness and playfulness of US law. However, the dividends of millions of dollars per quarter fall into Yang Rui's hands, which is enough to solve the problem of attorney fees.

In this way, Yang Rui naturally had no urge to sell catalyst patents.

However, if Yang Rui invests too much in researching new drugs, things will become completely different.

Arnold was not completely sure how many shares Yang Rui had in Huarui Company, but through many aspects of understanding, Arnold confirmed that Yang Rui had shares. The lawyer who helped Yang Rui establish a company back then was a relationship with Jilikan. Although Arnold could not ask about the specific details, there was always a brief message.

Van Lunding didn't understand Arnold's purpose, so he said from a research perspective: "When new drugs are being studied, everyone will carefully control the progress and scale of the research..."

"Yang Rui has never done new drug research before. If you give him suggestions, he might implement it."

"You want to send me to Huarui Laboratory for guidance?"

"Well, help them advance the experimental progress and push it faster..." The initial cost of new drug research is not high, but the later cost is a bottomless pit.

Van Lunding didn't think this was of any use, but he still agreed.

The next day, Van Lunding arrived at Huarui Laboratory and then found that he seemed to be really wrong.

The research progress of Huarui Laboratory is much faster than he imagined.
Chapter completed!